NASDAQ · TMCI
Healthcare · Medical - Devices
$4.60
Up+$0.13 (+2.82%)
Updated Aug 28, 2026, 3:02 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TMCI closed at $4.60 after 21 trading sessions, up 5.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $4.72 | $4.78 | $4.405 | $4.60 | 226.05K |
| Aug 26, 2026 | $4.78 | $4.80 | $4.59 | $4.72 | 217.75K |
| Aug 25, 2026 | $4.70 | $5.01 | $4.58 | $4.81 | 595.11K |
| Aug 24, 2026 | $4.34 | $4.40 | $4.25 | $4.37 | 348.15K |
| Aug 21, 2026 | $4.46 | $4.54 | $4.275 | $4.34 | 277.51K |
| Aug 20, 2026 | $4.50 | $4.51 | $4.30 | $4.46 | 271.1K |
| Aug 19, 2026 | $4.46 | $4.62 | $4.37 | $4.56 | 398.36K |
| Aug 18, 2026 | $4.46 | $4.66 | $4.41 | $4.45 | 227.16K |
| Aug 17, 2026 | $4.74 | $4.75 | $4.47 | $4.50 | 193.26K |
| Aug 14, 2026 | $4.52 | $4.79 | $4.48 | $4.79 | 245.39K |
| Aug 13, 2026 | $4.75 | $4.85 | $4.46 | $4.51 | 783.91K |
| Aug 12, 2026 | $4.72 | $4.83 | $4.50 | $4.75 | 459.88K |
| Aug 11, 2026 | $4.65 | $4.855 | $4.6108 | $4.74 | 472.39K |
| Aug 10, 2026 | $4.81 | $4.90 | $4.36 | $4.67 | 644.14K |
| Aug 7, 2026 | $5.13 | $5.198 | $4.47 | $4.76 | 880.02K |
| Aug 6, 2026 | $4.75 | $4.75 | $4.32 | $4.38 | 667.21K |
| Aug 5, 2026 | $4.73 | $4.83 | $4.39 | $4.78 | 685.39K |
| Aug 4, 2026 | $4.76 | $4.86 | $4.63 | $4.74 | 286.64K |
| Aug 3, 2026 | $4.32 | $4.74 | $4.28 | $4.68 | 373.77K |
| Jul 31, 2026 | $4.35 | $4.45 | $4.131 | $4.31 | 208.52K |
| Jul 30, 2026 | $4.03 | $4.395 | $4.03 | $4.38 | 289.44K |
The latest Smart Investors Daily articles mentioning TMCI.
TMCI research
Company profile and research snapshot.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Truist Securities | Hold | — |
| Jul 16, 2026 | Truist Securities | Hold | — |
| Mar 2, 2026 | Lake Street | Buy | — |
| Jan 7, 2026 | Stifel | Hold | — |
| Dec 18, 2025 | Truist Securities | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.
SeekingAlpha · Aug 7, 2026
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsTrip TaylorJohn Treace - Founder, Chairman &...
ChartMill · Aug 7, 2026
Treace Medical Q2: Revenue $45.4M in line, EPS -$0.24 beats -$0.30 estimate. FY guidance raised, stock up 9% pre-market.
Benzinga · Aug 7, 2026
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TMCI.
